This cannabidiol-forward formulation delivers 110 mg of CBD and 20 mg of CBG per pastille, supported by a 2.0% total terpene profile. The formulation is shaped by Limonene (0.60% w/w), beta-Caryophyllene (0.60% w/w) and Pinene (0.80% w/w), creating a balanced chemotype with a mild uplift and a steady functional profile across daytime and evening use.

Southern Sky CBD+ Pastilles are manufactured in Australia using a gelatin base with MCT oil as the carrier and CO₂-extracted cannabinoids. Small-batch production ensures precise cannabinoid distribution, stable texture, and dependable terpene expression across all 60 units, reflecting Southern Sky’s emphasis on formulation consistency.

Anecdotally, patients describe a clear, balanced effect with gentle mood elevation, improved focus and a generally settling influence without sedation. Prescribers commonly select this profile for patients presenting with anxiety, low mood, inflammatory symptoms, behavioural dysregulation or sleep disturbance, with reports of steady cognitive function and a calm, moderated emotional response.

As with all oral cannabinoid products, the slower onset and extended duration should be considered when determining timing and dose. Initiating therapy with gradual titration is generally recommended to identify individual response patterns.